Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) is one of the 17 biotechnology stocks with more than 50% upside. On February 3, the price target on Ultragenyx Pharmaceutical (NASDAQ:RARE) was set to $60 by H.C. Wainwright analyst Ram Selvaraju, who maintained a Buy rating on the stock. The analyst’s estimate leads to a promising upside potential of more than 155% from the prevailing level. Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why Pressmaster/Shutterstock.com Selvaraju attributed his views t ...